Grünenthal and DKSH expand four pain medicines across eight Asia-Pacific markets
AI Summary- Grünenthal and DKSH agreed to commercialise four pain medicines across eight Asia-Pacific markets.
- Eight markets will receive up to four medicines each, pending local regulatory approvals.
- DKSH began commercialising selected Grünenthal medicines in Asia-Pacific under their 2023 partnership.